Evolus (NASDAQ:EOLS) Stock Price Expected to Rise, Barclays Analyst Says

Evolus (NASDAQ:EOLS) had its price objective raised by Barclays from $20.00 to $22.00 in a report released on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective indicates a potential upside of 54.60% from the stock’s previous close.

Several other research firms have also issued reports on EOLS. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Tuesday, January 21st.

Evolus Trading Down 3.6 %

Shares of NASDAQ:EOLS opened at $14.23 on Monday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market cap of $901.04 million, a price-to-earnings ratio of -15.64 and a beta of 1.32. The company’s fifty day simple moving average is $11.88 and its 200 day simple moving average is $13.85. Evolus has a 12 month low of $9.25 and a 12 month high of $17.82.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Barclays PLC grew its holdings in shares of Evolus by 268.0% during the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after purchasing an additional 68,213 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Evolus by 173.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after acquiring an additional 265,635 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Evolus by 47.0% during the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after acquiring an additional 29,396 shares in the last quarter. Lord Abbett & CO. LLC grew its position in Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after acquiring an additional 188,685 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Evolus by 63.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock worth $2,753,000 after purchasing an additional 65,972 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.